Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2011 1
2013 1
2019 3
2020 3
2022 2
2023 3
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Bril V, Drużdż A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ; MG0003 study team. Bril V, et al. Lancet Neurol. 2023 May;22(5):383-394. doi: 10.1016/S1474-4422(23)00077-7. Lancet Neurol. 2023. PMID: 37059507 Clinical Trial.
Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study.
Querol L, De Sèze J, Dysgaard T, Levine T, Rao TH, Rivner M, Hartung HP, Kiessling P, Shimizu S, Marmol D, Bozorg A, Colson AO, Massow U, Eftimov F; CIDP01 Study Investigators. Querol L, et al. J Neurol Neurosurg Psychiatry. 2024 Aug 16;95(9):845-854. doi: 10.1136/jnnp-2023-333112. J Neurol Neurosurg Psychiatry. 2024. PMID: 38729747 Free PMC article. Clinical Trial.
Juvenile neuronal ceroid lipofuscinosis (JNCL) and the eye.
Bozorg S, Ramirez-Montealegre D, Chung M, Pearce DA. Bozorg S, et al. Surv Ophthalmol. 2009 Jul-Aug;54(4):463-71. doi: 10.1016/j.survophthal.2009.04.007. Surv Ophthalmol. 2009. PMID: 19539834 Free PMC article. Review.
Efficacy and tolerability of adjunctive lacosamide in patients aged <4 years with focal seizures.
Makedonska I, Ng YT, Beller C, Bozorg A, Csikós J, McClung C, Moeltgen H, Farkas MK; SP0967 Study Group. Makedonska I, et al. Ann Clin Transl Neurol. 2024 Mar;11(3):768-779. doi: 10.1002/acn3.52004. Epub 2024 Feb 20. Ann Clin Transl Neurol. 2024. PMID: 38375995 Free PMC article. Clinical Trial.
Region-specific primary efficacy variables were based on 72-h video-electroencephalograms: change in average daily frequency (ADF) of electrographic focal seizures as measured on end-of-maintenance video-electroencephalogram versus end-of-baseline video-electroencephalogra …
Region-specific primary efficacy variables were based on 72-h video-electroencephalograms: change in average daily frequency (ADF) of …
Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
Fahimi F, Tabarsi P, Kobarfard F, Bozorg BD, Goodarzi A, Dastan F, Shahsavari N, Emami S, Habibi M, Salamzadeh J. Fahimi F, et al. Int J Tuberc Lung Dis. 2013 Dec;17(12):1602-6. doi: 10.5588/ijtld.13.0019. Int J Tuberc Lung Dis. 2013. PMID: 24200276
METHODS: The study was performed among 60 pulmonary tuberculosis (TB) in-patients at a tertiary care university-affiliated hospital in Tehran, Iran. Drug samples were drawn 2 and 6 h post dose for isoniazid (INH), rifampicin (RMP) and pyrazinamide (PZA); related concentrat …
METHODS: The study was performed among 60 pulmonary tuberculosis (TB) in-patients at a tertiary care university-affiliated hospital in Tehra …
Gender differences in motor and non-motor symptoms in individuals with mild-moderate Parkinson's disease.
Abraham A, Bay AA, Ni L, Schindler N, Singh E, Leeth E, Bozorg A, Hart AR, Hackney ME. Abraham A, et al. PLoS One. 2023 Jan 11;18(1):e0272952. doi: 10.1371/journal.pone.0272952. eCollection 2023. PLoS One. 2023. PMID: 36630320 Free PMC article.
METHODS: 199 (127 men and 72 women; M age: 69.088.94) individuals with mild-moderate idiopathic PD (Hoehn &Yahr (H&Y) Median = 2, stages I-III) from a large metro area in the southeastern US were included in this retrospective, cross-sectional study. ...
METHODS: 199 (127 men and 72 women; M age: 69.088.94) individuals with mild-moderate idiopathic PD (Hoehn &Yahr (H&Y) Median …
Pharmacokinetics, safety, and tolerability of intravenous brivaracetam in pediatric patients with epilepsy: An open-label trial.
Farkas MK, Kang H, Fogarasi A, Bozorg A, James GD, Krauwinkel W, Morita D, Will E, Elshoff JP. Farkas MK, et al. Epilepsia. 2022 Apr;63(4):855-864. doi: 10.1111/epi.17187. Epub 2022 Feb 23. Epilepsia. 2022. PMID: 35196395 Free PMC article.
In the 15-min infusion group, geometric mean (GeoMean) BRV concentrations 15 (2) min (n = 21) and 3 h (15 min) (n = 21) post dose were 1903.0 ng/mL (geometric coefficient of variation [GeoCV]: 60.7%) and 1130.3 ng/mL (58.8%), respectively. In the bolus group, GeoMean BRV c …
In the 15-min infusion group, geometric mean (GeoMean) BRV concentrations 15 (2) min (n = 21) and 3 h (15 min) (n = 21) post dose wer …
Safety, tolerability, and efficacy of adjunctive lacosamide in pediatric patients with epilepsy syndromes associated with generalized seizures: Phase 2, open-label exploratory trial.
Auvin S, Arzimanoglou A, Beller C, Floricel F, Daniels T, Bozorg A. Auvin S, et al. Epilepsia. 2023 Nov;64(11):2947-2957. doi: 10.1111/epi.17741. Epub 2023 Aug 23. Epilepsia. 2023. PMID: 37545406 Clinical Trial.
There were no clinically significant mean or median changes or worsening from baseline to end of the titration period in the count of generalized spike-wave discharges per interpretable hour on 24-h ambulatory electroencephalogram recordings, or from baseline to the mainte …
There were no clinically significant mean or median changes or worsening from baseline to end of the titration period in the count of genera …
16 results